Pronova BioPharma ASA

Pronova BioPharma ASA (OSL:PRON) Pronova BioPharma ASA (OSE: PRON.OL) ("Pronova BioPharma" or the "company") has on 17 November 2008 purchased 37 000 of its own shares in the market at a price of NOK 23,10. After this transaction, the company holds 200 000 shares. Pronova BioPharma ASA has entered into an agreement to sell 200 000 of the company's shares to Per-Oluf Olsen, who will take over as CEO of the company after Tomas Settevik. This sale will be effected once Per-Oluf Olsen has assumed the position of CEO. Following the completion of these transactions, Pronova BioPharma ASA will not hold any of its own shares. Today's transaction ends the company's share buy back.

Pronova BioPharma ASA (OSL:PRON) Pronova BioPharma ASA (OSE: PRON.OL) ("Pronova BioPharma" or the "company") has on 14 November 2008 purchased 54 000 of its own shares in the market at a price of NOK 23,00 per share and intends to purchase an additional 37 000 shares in the market. After this transaction, the company holds 163 000 shares. Pronova BioPharma ASA has entered into an agreement to sell 200 000 of the company's shares to Per-Oluf Olsen, who will take over as CEO of the company after Tomas Settevik. This sale will be effected once Per-Oluf Olsen has assumed the position of CEO. Following the completion of these transactions, Pronova BioPharma ASA will not hold any of its own shares.

Pronova BioPharma ASA (OSL:PRON) Pronova BioPharma ASA (OSE: PRON.OL) ("Pronova BioPharma" or the "company") has on 12 November 2008 purchased 50 000 of its own shares in the market at a price of NOK 20,92 per share and intends to purchase an additional 91 000 shares in the market. After this transaction, the company holds 109 000 shares. Pronova BioPharma ASA has entered into an agreement to sell 200 000 of the company's shares to Per-Oluf Olsen, who will take over as CEO of the company after Tomas Settevik. This sale will be effected once Per-Oluf Olsen has assumed the position of CEO. Following the completion of these transactions, Pronova BioPharma ASA will not hold any of its own shares.

Pronova BioPharma ASA (OSL:PRON) Pronova BioPharma ASA (OSE: PRON.OL) ("Pronova BioPharma" or the "company") has on 11 November 2008 purchased 37 000 of its own shares in the market at a price of NOK 19,95 per share and intends to purchase an additional 141 000 shares in the market. After this transaction, the company holds 59 000 shares. Pronova BioPharma ASA has entered into an agreement to sell 200 000 of the company's shares to Per-Oluf Olsen, who will take over as CEO of the company after Tomas Settevik. This sale will be effected once Per-Oluf Olsen has assumed the position of CEO. Following the completion of these transactions, Pronova BioPharma ASA will not hold any of its own shares.

Pronova BioPharma ASA (OSL:PRON) 11 November, 2008, Lysaker, Norway: Pronova BioPharma ASA (OSE: PRON.OL) ("Pronova BioPharma" or the "company") today announces that a study to be presented at the American Heart Association Scientific Sessions in New Orleans, USA, shows that Lovaza/Omacor co-administered with atorvastatin significantly improves non-HDL cholesterol and triglycerides compared with atorvastatin alone. An abstract of the study was published on the AHA's conference website http://www.abstractsonline.com/plan/start.aspx?mkey=%7BD78A4520%2D4797%2D409B%2DBF84%2D2F89D1773D57%7D .

Pronova BioPharma ASA (OSL:PRON) 10 November, 2008, Lysaker, Norway: Primary insider, vice president legal affairs, Cecilia Orheim, has today bought 38 400 shares in the company.The shares were bought at an average share price of NOK 19.47. Ms Orheim's total number of shares held after todays purchase is 74 400.

Pronova BioPharma ASA (OSL:PRON) 5 November 2008, Lysaker, Norway: Pronova BioPharma ASA (OSE: PRON.OL) ("Pronova BioPharma" or the "company") today announces that its subsidiary Pronova BioPharma Norge AS has entered into a strategic supply agreement with Defiante Farmacêutica SA, a subsidiary of the Italian sigma-tau group, for the exclusive supply of the active pharmaceutical ingredient (API) for a fixed dose combination product with Omacor and simvastatin in Spain, France and Portugal, with a possibility to add other countries upon prior written agreement.

Pronova BioPharma ASA (OSL:PRON) 4 November, 2008, Lysaker, Norway: Primary insider Solveig Hellebust (Vice President HR and Communications ) has today through her wholly owned company Guldheim AS sold 25500 shares in Pronova BioPharma ASA at an average price of NOK 19.92 per share. After this transaction Mrs. Solveig Hellebust (and related parties) hold 776000 shares in the company.

Pronova BioPharma ASA (OSL:PRON) Pronova BioPharma posted strong third quarter results, driven by robust end-user demand and consistent performance at the Sandefjord plant. In-sourcing of intermediaries has facilitated the increase of the production forecast for 2009 to 1 400-1 500 tonnes. Positive results for the GISSI-heart failure trial were published at the European Society of Cardiology in August. Both primary endpoints were met.

Pronova BioPharma ASA (OSL:PRON) 4 November 2008, Lysaker, Norway: Pronova BioPharma ASA (OSE: PRON.OL) announced today that the board of directors has appointed Per-Oluf Olsen as chief executive officer to succeed Tomas Settevik, who has informed the board that he wishes to stand down from his position as CEO.